Eye doctors fighting Genentech decision

The California Academy of Eye Physicians and Surgeons has issued a call for South San Francisco’s Genentech Inc. (DNA) to reverse its decision to halt sales of its drug Avastin to compounding pharmacies effective November 30, 2007.

The group is asking the California Medical Association and possibly the American Medical Association to take a stand on the issue as well.

Opthalmologists have been using Avastin, a drug currently only approved for cancer, to treat age-related macular degeneration, a common eye disease. Because only a small portion of a standard dose is needed for eye treatment, eye doctors have generally purchased the drug from compounding pharmacies, which repackage it in smaller doses.

Genentech, however, also sells a similar but much more expensive drug, Lucentis, which according to information provided by the physicians sells for approximately $2,000 a dose versus approximately $40 a dose for Avastin.

businessBusiness & Real Estate

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

School district, teachers reach tentative agreement on distance learning

With less than two weeks until the start of the school year,… Continue reading

Boudin, Gascon defend NFL in controversy over Stephon Clark video

Public service announcement prompted pushback from California prosecutors association

State bill would allow families of police brutality victims to seek compensation

A group of state and local officials on Thursday joined two family… Continue reading

Retired officers seek end to decade-old age discrimination case

Retired officer Juanita Stockwell was 60 when she and her colleagues first… Continue reading

San Francisco schools estimate $25m needed to close digital divide

Private donations being sought to fund internet access, technology

Most Read